Open Label Study to Evaluate Effect, Safety and Tolerability of Betaferon Standard Dose of 250µg in Patients of Chinese Origin With Multiple Sclerosis

Open Label Study to Evaluate the Effect, Safety and Tolerability of 250µg (8 MIU) Interferon Beta 1b (Betaferon) Given Subcutaneously Every Other Day (for 24 Weeks) in Patients of Chinese Origin With Multiple Sclerosis

The purpose of this study is to determine if the study drug is effective and safe in the treatment of Multiple Sclerosis (MS) in patients of Chinese origin.

The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer HealthCare AG, Germany.

Bayer HealthCare AG, Germany is the sponsor of the trial.

Inclusion Criteria:

• Chinese origin
• diagnosis of Relapsing remitting multiple sclerosis or secondary progressive multiple sclerosis

Exclusion Criteria:

• Any disease other than Multiple Sclerosis (MS) that could better explain the patients signs and symptoms
• HIV (human immunodeficiency virus) infections
• Hepatitis A
• Syphilis
• immunodeficiency
• rheumatic disease or Sjogren syndrome
• heart disease
• severe depression
• pregnancy or lactation
• conditions interfering with Magnetic Resonance Imaging (MRI)
• Gadolinium DTPA (Gadovist, contrast agent) allergy
• allergy against human proteins, paracetamol, acetaminophen and ibuprofen intolerance
• participation in other trial